<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Fink SP</submitter><funding>NCI NIH HHS</funding><pagination>291-8</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4322189</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>36(2)</volume><pubmed_abstract>Non-steroidal anti-inflammatory drugs prevent colorectal cancer by inhibiting cyclooxygenase (COX) enzymes that synthesize tumor-promoting prostaglandins. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) is a tumor suppressor that degrades tumor-promoting prostaglandins. Murine knockout of 15-PGDH increases susceptibility to azoxymethane-induced colon tumors. It also renders these mice resistant to celecoxib, a selective inhibitor of inducible COX-2 during colon neoplasia. Similarly, humans with low colonic 15-PGDH are also resistant to colon adenoma prevention with celecoxib. Here, we used aspirin and sulindac, which inhibit both COX-1 and COX-2, in order to determine if these broader COX inhibitors can prevent colon tumors in 15-PGDH knockout (KO) mice. Unlike celecoxib, sulindac proved h</pubmed_abstract><journal>Carcinogenesis</journal><pubmed_title>Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.</pubmed_title><pmcid>PMC4322189</pmcid><funding_grant_id>N01 CN-43302</funding_grant_id><funding_grant_id>P50 CA150964</funding_grant_id><pubmed_authors>Dawson DM</pubmed_authors><pubmed_authors>Markowitz SD</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Yang P</pubmed_authors><pubmed_authors>Kresak A</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors><pubmed_authors>Willis JE</pubmed_authors><pubmed_authors>Kopelovich L</pubmed_authors><pubmed_authors>Barnholtz-Sloan JS</pubmed_authors><pubmed_authors>Fink SP</pubmed_authors><pubmed_authors>Lawrence EG</pubmed_authors></additional><is_claimable>false</is_claimable><name>Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.</name><description>Non-steroidal anti-inflammatory drugs prevent colorectal cancer by inhibiting cyclooxygenase (COX) enzymes that synthesize tumor-promoting prostaglandins. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) is a tumor suppressor that degrades tumor-promoting prostaglandins. Murine knockout of 15-PGDH increases susceptibility to azoxymethane-induced colon tumors. It also renders these mice resistant to celecoxib, a selective inhibitor of inducible COX-2 during colon neoplasia. Similarly, humans with low colonic 15-PGDH are also resistant to colon adenoma prevention with celecoxib. Here, we used aspirin and sulindac, which inhibit both COX-1 and COX-2, in order to determine if these broader COX inhibitors can prevent colon tumors in 15-PGDH knockout (KO) mice. Unlike celecoxib, sulindac proved h</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015 Feb</publication><modification>2025-04-21T22:25:38.496Z</modification><creation>2019-03-27T01:44:54Z</creation></dates><accession>S-EPMC4322189</accession><cross_references><pubmed>25503930</pubmed><doi>10.1093/carcin/bgu241</doi></cross_references></HashMap>